Applying the #ACR24 #LupusNephritis: Case 2 by Dr M Dall’Era @RheumNow https://t.co/A7i103uHZT

• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1
• https://x.com/KDAO2011/status/1858535623595835495/photo/1

Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that? I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis #ACR24 @RheumNow Abstr#2391 https://t.co/FWgCjEwPDK

• https://x.com/EBRheum/status/1858536139990188151/photo/1

Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%). @RheumNow #ACR24 #GCTox

Biosimilar switching in practice Hyrich: UK experience Switching to biosimilar has no immediate benefit to patients but saves NHS money Allows for gain share that can be re-invested in pt care Transparency in switching in explaining to pts and offering resource @RheumNow #ACR24

Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset @RheumNow #ACR24 https://t.co/TLDSiBZZPs

• https://x.com/AkhilSoodMD/status/1858536391875113060/photo/1

Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

• https://x.com/i/web/status/1858536895019438208
• https://x.com/synovialjoints/status/1858536895019438208/photo/1

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

• https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1

Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu

• https://x.com/ericdeinmd/status/1858537804281626625/photo/1
• https://x.com/ericdeinmd/status/1858537804281626625/photo/1

Food for thought 🤔 Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were higher among individuals with incident SpA compared to controls @RheumNow #ACR24 https://t.co/qUXcxSfTxE

• https://x.com/AkhilSoodMD/status/1858537901753319481/photo/1

Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use But is T2T met? LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA #ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq

• https://x.com/JihaRheum/status/1858537901757239324/photo/1

Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp

• https://x.com/Dr_Brian_MD/status/1858538311314235670/photo/1

Abstract 1912: Time to close the gaps in #PsA care RISE Registry reveals: - higher disease activity in the South - more oral steroids + csDMARDs, fewer bDMARDs, and more comorbidities in the Midwest @RheumNow #ACR24

Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic @andreafava why isn't this just more-testing & more-sensitive testing shifting the phenotype of who we diagnose? #ACR24 @RheumNow Abstr#2413 https://t.co/o2e9TFMsUp

• https://x.com/EBRheum/status/1858539160019050703/photo/1
• https://x.com/EBRheum/status/1858539160019050703/photo/1
• https://x.com/EBRheum/status/1858539160019050703/photo/1

Lots of data on TYKs including much supporting efficacy in interferon inhibition Can we really call interferon signalling a "central" pathway in SLE? Inhibiting it has been modestly successful, at best, and mostly for skin dx #ACR24 @RheumNow Abstr#2434 https://t.co/Q94FQz3gzO

• https://x.com/EBRheum/status/1858540166723359064/photo/1

#2222 📊 New data on #RA-ILD: 🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incidence at 5 years (IR 14.9/1000 PY). 🔴ILD often precedes or coincides with RA onset. 🔴NSIP > UIP 🔴airway involvement less common than expected. #acr24 @RheumNow